Interaction Between Decidual Cells and NK Cells in Endometriosis (PAINLESS)
Interaction Between Decidual Cells and Natural Killer Cells in Endometriosis: A Prospective Pilot Case-Control Study
Endometriosis is a chronic gynecological disease characterized by the presence of endometrial-like tissue outside the uterus and is frequently associated with pelvic pain and infertility. Increasing evidence suggests that immune dysfunction may contribute to the development and persistence of the disease.
The purpose of this prospective case-control study is to compare immune cell characteristics in women with deep endometriosis and women without endometriosis during the secretory phase of the menstrual cycle. Participants will undergo collection of clinical data, blood samples, endometrial samples, and vaginal microbiota samples. For participants undergoing clinically indicated pelvic surgery, additional biological samples may be collected during the procedure. The study aims to improve understanding of the immune mechanisms involved in endometriosis and to identify potential biomarkers associated with the disease.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Endometriosis affects approximately 10-15% of women of reproductive age and represents a major public health concern. Despite its high prevalence, the pathophysiological mechanisms underlying the disease remain incompletely understood. Increasing evidence suggests that alterations in the immune environment of the endometrium may contribute to the establishment and progression of endometriosis. In particular, uterine immune cells may play a role in regulating local inflammation and tissue homeostasis. Characterizing these immune mechanisms may improve understanding of disease development and identify potential biomarkers associated with endometriosis.
PAINLESS is a prospective, single-center, pilot case-control study conducted at Foch Hospital (Suresnes, France). The study will enroll 50 adult women, including 25 participants with confirmed deep endometriosis and 25 control participants without endometriosis.
Biological samples will be collected during the secretory phase of the menstrual cycle (days 16-24). Depending on clinical management, study procedures may include:
- Collection of demographic and clinical data
- Assessment of symptoms and quality of life
- Blood sampling
- Endometrial sampling
- Vaginal microbiota sampling
- Collection of additional biological specimens during clinically indicated pelvic surgery.
Biological samples will be analyzed to characterize immune cell populations, evaluate soluble immune mediators, investigate associations with hormonal and clinical parameters, and explore biological mechanisms involved in endometriosis.The primary objective is to compare the expression of immune-related markers in endometrial and peritoneal samples obtained from women with endometriosis and controls. Secondary objectives include characterization of immune cell phenotypes and functions, evaluation of immune-related soluble factors, investigation of interactions between immune and endometrial cells, assessment of correlations with hormonal and clinical data, exploratory genetic analyses, and creation of a vaginal microbiota biobank. Results from this pilot study are expected to provide preliminary data for future research aimed at improving the understanding, diagnosis, and management of endometriosis.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Florence Couppey, clinical project manager
- Numéro de téléphone: +33 (0)1 46 25 31 30
- E-mail: f.couppey@hopital-foch.com
Lieux d'étude
-
-
-
Suresnes, France, 92150
- Hôpital Foch
-
Contact:
- Florence COUPPEY, Clinical project manager
- Numéro de téléphone: +33(0)1 46 25 31 30
- E-mail: f.couppey@hopital-foch.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Endometriosis Group
- Female participant aged 18 years or older.
- Confirmed diagnosis of deep endometriosis by imaging or surgery.
- Pelvic pain and/or severe dysmenorrhea (Visual Analog Scale > 4).
- Premenopausal.
- No contraceptive or hormonal treatment during the study menstrual cycle.
- Affiliated with a health insurance system.
- Able and willing to provide written informed consent.
- Control Group
- Female participant aged 18 years or older.
- No diagnosis of endometriosis.
- Premenopausal.
- No contraceptive or hormonal treatment during the study menstrual cycle.
- No chronic pelvic pain or severe dysmenorrhea (Visual Analog Scale < 4).
- Affiliated with a health insurance system.
- Able and willing to provide written informed consent.
Exclusion Criteria:
- Current infection.
- Active cancer.
- Active autoimmune disease.
- Concomitant hormonal treatment.
- Pregnancy.
- Participant under guardianship or legal protection.
- Participant deprived of liberty.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Endometriosis Group
Adult women with confirmed deep endometriosis undergoing collection of clinical data and biological samples, including blood, endometrial tissue, vaginal microbiota samples, and, when clinically indicated, additional samples collected during pelvic surgery.
|
Collection of blood samples, endometrial samples, vaginal microbiota samples, and surgical specimens when clinically indicated for immunological and biomarker analyses.
|
|
Comparateur actif: Control Group
Adult women without endometriosis undergoing collection of clinical data and biological samples, including blood, endometrial tissue, vaginal microbiota samples, and, when clinically indicated, additional samples collected during pelvic surgery.
|
Collection of blood samples, endometrial samples, vaginal microbiota samples, and surgical specimens when clinically indicated for immunological and biomarker analyses.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
CD39 Expression on Natural Killer Cells in Endometrial and Peritoneal Samples
Délai: At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
|
Comparison of CD39 expression on natural killer (NK) cells in endometrial and peritoneal samples collected from women with deep endometriosis and women without endometriosis.
|
At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
NK Cell Cytotoxic Function
Délai: At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
|
Assessment of NK cell cytotoxic activity through degranulation markers and cytokine production in biological samples.
|
At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
|
|
Endometrial and NK Cell Interactions
Délai: At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
|
Evaluation of interactions between endometrial cells and NK cells using tissue-based analyses.
|
At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
|
|
Ex Vivo Modulation of NK Cell Function
Délai: Following sample collection, up to study completion (16 months)
|
Evaluation of the effects of cytokine stimulation on NK cell function and endometrial cell responses in laboratory assays.
|
Following sample collection, up to study completion (16 months)
|
|
Association Between Hormonal Levels and NK Cell Profile
Délai: At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
|
Correlation of estrogen and progesterone levels with NK cell characteristics and immune markers.
|
At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
|
|
Association Between Clinical Characteristics and Immune Markers
Délai: At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
|
Correlation between clinical features of endometriosis and immunological findings.
|
At sample collection during the secretory phase of the menstrual cycle (Days 16-24)
|
|
Genetic Biomarker Associations
Délai: At sample collection and laboratory analysis up to study completion (16 months)
|
Assessment of associations between genetic markers and immunological findings.
|
At sample collection and laboratory analysis up to study completion (16 months)
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Marie CARBONNEL, MD, Foch Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- La douleur
- Manifestations neurologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladies génitales, femme
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Endométriose
- Douleur pelvienne
Autres numéros d'identification d'étude
- 2024_0074
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .